FDA Moves to Ban Compounded Semaglutide and Tirzepatide: What Researchers Need to Know
Industry Pulse › FDA Moves to Ban Compounded Semaglutide and Tirzepatide
May 1, 2026 · Regulatory
On May 1, 2026, the FDA filed a proposal that would effectively end large-scale compounding of semaglutide, tirzepatide, and liraglutide in the United States. These are the active ingredients in Ozempic, Wegovy, Mounjaro, Zepbound, Victoza, and Saxenda. If the proposal is finalized after the comment period closes on June 30, the compounding pharmacies that have been producing low-cost copies of these drugs will lose the legal basis to keep doing it. The brand-name versions stay on the market. The cheap copies do not.
This matters because compounded GLP-1s have been one of the largest off-label drug markets in the country for the past three years. Wiping out that supply is a significant regulatory event, and the reasoning the FDA used to do it has implications well beyond GLP-1s.
What a 503B Facility Actually Is
To understand what just happened, you need to understand what a 503B outsourcing facility is and why it exists.
A 503B is a high-volume compounding operation. Think of it as a small-scale pharmaceutical manufacturer. Regular pharmacies (called 503As) compound medications one prescription at a time for individual patients. 503Bs operate at a different scale entirely, producing thousands of vials in batches and shipping them to clinics, hospitals, and telehealth platforms.
503Bs exist for a specific reason: when an FDA-approved drug is in shortage, 503Bs can step in and produce a copy. This is the legal pathway that opened up compounded semaglutide and tirzepatide in the first place. Demand for Ozempic and Mounjaro outstripped supply starting in 2022, the FDA declared shortages, and 503Bs began compounding GLP-1 versions at roughly 80 to 90 percent off the brand-name price.
Why the Shortage Loophole Already Closed
The shortage pathway was always going to be temporary. Once Novo Nordisk and Eli Lilly caught up with demand, the FDA could declare the shortages resolved and pull the legal basis for compounding.
That’s exactly what happened. Tirzepatide came off the shortage list in late 2024. Semaglutide came off in early 2025. By mid-2025, the legal cover that compounders had relied on was gone, and the FDA started enforcement.
But there was still one door left open. The 503B Bulks List.
What the Bulks List Is and Why It Matters
The 503B Bulks List is a different legal pathway, separate from the shortage list. Substances on the bulks list can be compounded by 503B facilities regardless of whether there’s a shortage. The list is FDA-curated, narrow, and slow to update.
For most of 2024 and 2025, compounders and their trade associations were lobbying hard to get semaglutide and tirzepatide added to the bulks list. If they made the list, the compounded GLP-1 industry could keep operating even after the shortages were officially over. It was the last available off-ramp.
On May 1, the FDA shut that off-ramp.
What the FDA Actually Said
The agency’s reasoning is narrow and surgical. Under the law, a substance only goes on the bulks list if there’s a “clinical need” for compounded versions, meaning the FDA-approved drug isn’t suitable for some group of patients who genuinely require something different.
The FDA looked at the petitions and concluded the case wasn’t there. Wegovy and Ozempic exist. Mounjaro and Zepbound exist. The petitioners didn’t show why these approved drugs couldn’t meet the needs of the patients who would use compounded versions. Without that showing, the legal standard for adding a substance to the bulks list isn’t met.
The agency also pointed to safety concerns: more than 455 reports of adverse events tied to compounded semaglutide and more than 320 tied to compounded tirzepatide as of early 2025, many involving patients drawing wrong doses from multidose vials. Counterfeit supply was cited as well. The safety record gives the FDA a defensible position if compounders or their trade groups challenge the proposal in court.
What This Does Not Touch
This proposal is narrowly scoped. It is important to be clear about what it does and does not reach.
It does not affect FDA-approved Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda, or Victoza. Those continue to be sold through normal pharmacy channels with prescriptions. Anyone using these drugs through standard medical care is unaffected.
It does not directly govern 503A pharmacies, the smaller patient-specific operations. 503As work under a separate set of rules and have their own bulks list. However, the FDA has historically used reasoning from one framework to inform action on the other, so 503A action on the same compounds is plausible going forward.
It does not reach research-use-only suppliers. RUO compounds are not sold for human use, are not compounded into finished drug products, and sit outside the 503A and 503B regulatory perimeter entirely. The bulks list determinations do not apply to research peptide supply.
Why This Story Is Bigger Than GLP-1s
The most important thing about the May 1 proposal is not what it did to compounded Ozempic copies. It is the framework the FDA used to do it.
The “clinical need” standard the FDA applied here is portable. The same logic can be used against any compound where an FDA-approved alternative exists. As the pipeline of approved obesity and metabolic drugs expands, so does the FDA’s ability to use the bulks list as a tool for narrowing the compounding space.
This signals a regulatory direction. Expect the same framework to be applied to other compounds the FDA wants to push out of the compounding pathway over the next 12 to 24 months.
What This Means for the Research Peptide Industry
For research-use-only suppliers, the direct regulatory impact is minimal. The 503A and 503B frameworks govern compounding for human therapeutic use, which is a different category from research peptides.
The indirect implications matter more.
Acquiring banks, payment processors, and merchant services providers track FDA enforcement actions closely. Visible regulatory tightening in adjacent verticals tends to ripple outward. Expect incremental friction in payment processing for research peptide operations even where no direct regulatory action applies, because the underwriting models that govern these decisions are not surgical.
The reasoning is also exportable to other compounds researchers care about. Retatrutide is in late-stage clinical development at Eli Lilly, and once it has FDA approval, the same bulks list framework could be applied to compounded retatrutide. Similar logic applies to any developmental peptide that ends up with an approved drug analog. For more on the compounds in this category, see Metabolic Peptide Research.
The comment period through June 30 is the procedural window for stakeholders to push back on the determination. Comments go through Regulations.gov under docket FDA-2018-N-3240. Whether the final rule shifts in response to comments will tell the industry how rigid the FDA intends to be on this framework going forward.
What to Watch Next
Three things to watch over the next 90 days.
First, the comment period response. Compounding trade associations and 503B operators will push hard. The substance and structure of the FDA’s final determination will signal whether the agency is open to negotiation on the framework or treating it as settled.
Second, the 503A side. If the FDA moves to apply similar reasoning to the 503A bulks list for the same compounds, the door closes on patient-specific compounding too. That is the bigger story for the broader compounding industry.
Third, retatrutide. It is the next major compound in the GLP-1 family expected to receive FDA approval. Once approved, the bulks list framework applied here becomes immediately relevant to compounded retatrutide as well. Researchers and laboratories tracking this compound should expect the same regulatory pattern to repeat.
For laboratory research applications, research-grade Retatrutide is available with batch-specific Certificate of Analysis and 99%+ purity confirmation by HPLC and mass spectrometry, documented for in vitro and non-clinical research use only.
FDA Moves to Ban Compounded Semaglutide and Tirzepatide: What Researchers Need to Know
FDA Moves to Ban Compounded Semaglutide and Tirzepatide: What Researchers Need to Know
On May 1, 2026, the FDA filed a proposal that would effectively end large-scale compounding of semaglutide, tirzepatide, and liraglutide in the United States. These are the active ingredients in Ozempic, Wegovy, Mounjaro, Zepbound, Victoza, and Saxenda. If the proposal is finalized after the comment period closes on June 30, the compounding pharmacies that have been producing low-cost copies of these drugs will lose the legal basis to keep doing it. The brand-name versions stay on the market. The cheap copies do not.
This matters because compounded GLP-1s have been one of the largest off-label drug markets in the country for the past three years. Wiping out that supply is a significant regulatory event, and the reasoning the FDA used to do it has implications well beyond GLP-1s.
What a 503B Facility Actually Is
To understand what just happened, you need to understand what a 503B outsourcing facility is and why it exists.
A 503B is a high-volume compounding operation. Think of it as a small-scale pharmaceutical manufacturer. Regular pharmacies (called 503As) compound medications one prescription at a time for individual patients. 503Bs operate at a different scale entirely, producing thousands of vials in batches and shipping them to clinics, hospitals, and telehealth platforms.
503Bs exist for a specific reason: when an FDA-approved drug is in shortage, 503Bs can step in and produce a copy. This is the legal pathway that opened up compounded semaglutide and tirzepatide in the first place. Demand for Ozempic and Mounjaro outstripped supply starting in 2022, the FDA declared shortages, and 503Bs began compounding GLP-1 versions at roughly 80 to 90 percent off the brand-name price.
Why the Shortage Loophole Already Closed
The shortage pathway was always going to be temporary. Once Novo Nordisk and Eli Lilly caught up with demand, the FDA could declare the shortages resolved and pull the legal basis for compounding.
That’s exactly what happened. Tirzepatide came off the shortage list in late 2024. Semaglutide came off in early 2025. By mid-2025, the legal cover that compounders had relied on was gone, and the FDA started enforcement.
But there was still one door left open. The 503B Bulks List.
What the Bulks List Is and Why It Matters
The 503B Bulks List is a different legal pathway, separate from the shortage list. Substances on the bulks list can be compounded by 503B facilities regardless of whether there’s a shortage. The list is FDA-curated, narrow, and slow to update.
For most of 2024 and 2025, compounders and their trade associations were lobbying hard to get semaglutide and tirzepatide added to the bulks list. If they made the list, the compounded GLP-1 industry could keep operating even after the shortages were officially over. It was the last available off-ramp.
On May 1, the FDA shut that off-ramp.
What the FDA Actually Said
The agency’s reasoning is narrow and surgical. Under the law, a substance only goes on the bulks list if there’s a “clinical need” for compounded versions, meaning the FDA-approved drug isn’t suitable for some group of patients who genuinely require something different.
The FDA looked at the petitions and concluded the case wasn’t there. Wegovy and Ozempic exist. Mounjaro and Zepbound exist. The petitioners didn’t show why these approved drugs couldn’t meet the needs of the patients who would use compounded versions. Without that showing, the legal standard for adding a substance to the bulks list isn’t met.
The agency also pointed to safety concerns: more than 455 reports of adverse events tied to compounded semaglutide and more than 320 tied to compounded tirzepatide as of early 2025, many involving patients drawing wrong doses from multidose vials. Counterfeit supply was cited as well. The safety record gives the FDA a defensible position if compounders or their trade groups challenge the proposal in court.
What This Does Not Touch
This proposal is narrowly scoped. It is important to be clear about what it does and does not reach.
It does not affect FDA-approved Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda, or Victoza. Those continue to be sold through normal pharmacy channels with prescriptions. Anyone using these drugs through standard medical care is unaffected.
It does not directly govern 503A pharmacies, the smaller patient-specific operations. 503As work under a separate set of rules and have their own bulks list. However, the FDA has historically used reasoning from one framework to inform action on the other, so 503A action on the same compounds is plausible going forward.
It does not reach research-use-only suppliers. RUO compounds are not sold for human use, are not compounded into finished drug products, and sit outside the 503A and 503B regulatory perimeter entirely. The bulks list determinations do not apply to research peptide supply.
Why This Story Is Bigger Than GLP-1s
The most important thing about the May 1 proposal is not what it did to compounded Ozempic copies. It is the framework the FDA used to do it.
The “clinical need” standard the FDA applied here is portable. The same logic can be used against any compound where an FDA-approved alternative exists. As the pipeline of approved obesity and metabolic drugs expands, so does the FDA’s ability to use the bulks list as a tool for narrowing the compounding space.
This signals a regulatory direction. Expect the same framework to be applied to other compounds the FDA wants to push out of the compounding pathway over the next 12 to 24 months.
What This Means for the Research Peptide Industry
For research-use-only suppliers, the direct regulatory impact is minimal. The 503A and 503B frameworks govern compounding for human therapeutic use, which is a different category from research peptides.
The indirect implications matter more.
Acquiring banks, payment processors, and merchant services providers track FDA enforcement actions closely. Visible regulatory tightening in adjacent verticals tends to ripple outward. Expect incremental friction in payment processing for research peptide operations even where no direct regulatory action applies, because the underwriting models that govern these decisions are not surgical.
The reasoning is also exportable to other compounds researchers care about. Retatrutide is in late-stage clinical development at Eli Lilly, and once it has FDA approval, the same bulks list framework could be applied to compounded retatrutide. Similar logic applies to any developmental peptide that ends up with an approved drug analog. For more on the compounds in this category, see Metabolic Peptide Research.
The comment period through June 30 is the procedural window for stakeholders to push back on the determination. Comments go through Regulations.gov under docket FDA-2018-N-3240. Whether the final rule shifts in response to comments will tell the industry how rigid the FDA intends to be on this framework going forward.
What to Watch Next
Three things to watch over the next 90 days.
First, the comment period response. Compounding trade associations and 503B operators will push hard. The substance and structure of the FDA’s final determination will signal whether the agency is open to negotiation on the framework or treating it as settled.
Second, the 503A side. If the FDA moves to apply similar reasoning to the 503A bulks list for the same compounds, the door closes on patient-specific compounding too. That is the bigger story for the broader compounding industry.
Third, retatrutide. It is the next major compound in the GLP-1 family expected to receive FDA approval. Once approved, the bulks list framework applied here becomes immediately relevant to compounded retatrutide as well. Researchers and laboratories tracking this compound should expect the same regulatory pattern to repeat.
For laboratory research applications, research-grade Retatrutide is available with batch-specific Certificate of Analysis and 99%+ purity confirmation by HPLC and mass spectrometry, documented for in vitro and non-clinical research use only.